Rohto Pharmaceutical Co., Ltd. (Headquarters: Osaka City, President: Hidetoshi Segi) has donated its 10th period of support funds from its "Social Partner Activity," conducted jointly with 10 retail business partners, to an organization engaged in international eye care support activities, as part of its efforts to support the "joy of seeing" for people around the world. This initiative began in 2016 and marks its 10th period this year. The total donation for the 10th period was \1,614,490, bringing the cumulative total donation since the 1st period to \18,741,850. Many people worldwide still face the risk of blindness due to conditions like cataracts. Rohto Pharmaceutical, together with its business partners, will continue to support efforts to resolve eye health challenges. ■What are Social Partners? Social Partners are retail business partners who, in conjunction with Rohto Pharmaceutical, donate a portion of their sales to social contribution activities such as medical support in Japan and worldwide. In this activity, we employ a matching gift system where partner companies contribute a portion of the sales of designated products, and Rohto Pharmaceutical matches that amount. This is a unique social contribution activity by Rohto Pharmaceutical where companies and distributors collaborate to expand the circle of support. The 10th period's donations were derived from a portion of sales from "V Rohto Premium," "V Rohto Contact Premium," "V Rohto Active Premium," "V Rohto Dry Eye Premium," and "Rohto Kodomo Soft" between December 1, 2025, and April 30, 2026. From left: "V Rohto Premium" (Class 2 OTC drug): For eye strain and redness. "V Rohto Contact Premium" (Class 3 OTC drug): For discomfort when wearing contact lenses. "V Rohto Active Premium" (Class 2 OTC drug): For blurred vision due to eye strain and excessive eye discharge. "V Rohto Dry Eye Premium" (Class 3 OTC drug): For dry eyes. "Rohto Kodomo Soft" (Class 3 OTC drug): For children's eye strain. Total Don